Targeted treatment for osteoarthritis: drugs and delivery system

Mao, Liwei; Wu, Wei; Wang, Miao; Guo, Jianmin; Li, Hui; Zhang, Shihua; Xu, Jiake; Zou, Jun

doi:10.1080/10717544.2021.1971798

Cited by 61 publications

(39 citation statements)

References 173 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, most of the clinical treatment strategies for OA focus on delaying the development of the disease, reducing pain, and improving motor functions. However, it is difficult to achieve an optimal therapeutic effect through traditional clinical treatment strategies due to the complexity of molecular and cellular alterations in the cartilage tissue of OA patients, the effective treatment of osteoarthritis has many obstacles and lacks a suitable cure ( Van Spil et al, 2019 ; Mao et al, 2021 ).…”

Section: Summary and Perspectivementioning

confidence: 99%

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis

et al. 2022

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common type of arthritis and the leading cause of disability globally. It tends to occur in middle age or due to an injury or obesity. OA occurs with the onset of symptoms, including joint swelling, joint effusion, and limited movement at a late stage of the disease, which leads to teratogenesis and loss of joint function. During the pathogenesis of this degenerative joint lesion, several local inflammatory responses are activated, resulting in synovial proliferation and pannus formation that facilitates the destruction of the bone and the articular cartilage. The commonly used drugs for the clinical diagnosis and treatment of OA have limitations such as low bioavailability, short half-life, poor targeting, and high systemic toxicity. With the application of nanomaterials and intelligent nanomedicines, novel nanotherapeutic strategies have shown more specific targeting, prolonged half-life, refined bioavailability, and reduced systemic toxicity, compared to the existing medications. In this review, we summarized the recent advancements in new nanotherapeutic strategies for OA and provided suggestions for improving the treatment of OA.

show abstract

Section: Summary and Perspectivementioning

confidence: 99%

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Carbon nanotubes had a greater absorption of dexamethasone by caveolin dependent endocytosis and effective intracellular distribution, inhibiting reactive oxygen species generation by targeting mitochondria. 81 Singh et al also explored the impact of functionalization density on murine macrophage cell lines using surface engineered multi-walled carbon nanotubes. The level of cellular absorption was shown to be precisely related to the surface hydrophobicity of nanotubes, which was speculated to be owing to cell receptors drawing up carbon nanotubes in a charged manner.…”

Section: Effective Utilization and Outcomes Of Carbon Nanotubes In Dr...mentioning

confidence: 99%

Carbon Nanotubes: An Optimistic Nanomaterial with Superfluity Characteristics in Drug Delivery for the Treatment of Arthritis

Srinivasan¹,

Palanisamy²

2022

Ind. J. Pharm. Edu. Res

View full text Add to dashboard Cite

Arthritis is chronic disease that affects the joint system and induces pain and inflammation in human body. Nanotechnology based drug delivery has progressed to be viable and more attractive for the treatment of arthritis. A carbon nanotube is one of the foremost prominent nanomaterials with high surface area utilized to exhibit stable release of drugs. Nonetheless, researchers have done investigations using either single-walled carbon nanotubes (SWCNT) or multi-walled carbon nanotubes (MWCNT) to gain optimistic results in targeted delivery for arthritis disorder. In this view, functionalized carbon nanotubes are employed to deliver drugs with higher accuracy and controlled release of drugs with less toxic effects. Unfortunately, very limited investigations are reported the prospective utilization of functionalized carbon nanotubes as eminent drug carriers for arthritis treatment. Moreover, the amounts of toxicity of carbon nanotubes, as well as their aggregation in cells and tissues are the key limits that must be considered evidently. The biosafety exposure of carbon nanotubes to humans are still a source of concern. As a result, more research is needed to solve the obstacles associated with carbon nanotubes in conjugation with drugs such as agglomeration, lack of solubility and interaction mechanism with drugs. In this review, we discussed the significant characteristics and outcomes of carbon nanotubes in drug delivery for the treatment of arthritis disease. The toxic level of carbon nanotubes is projected and why the incorporation of CNTs in drug delivery is still limited in various phases is highlighted. The biosafety aspects, cellular uptake mechanism and the importance of functionalization carbon nanotubes in drug delivery are reviewed.

show abstract

“…A recent trial evaluated the efficacy of intra-articular injection of platelet-rich plasma in osteoarthritis, but no satisfactory results were obtained with regard to improvement of knee pain or reduction of cartilage volume loss (Bennell et al 2021). Novel drug delivery systems, like dendrimers, microspheres and solid lipid nanoparticles that ensure efficient intra-articular drug delivery, are now being investigated (Mao et al 2021).…”

Section: Platelet Rich Plasmamentioning

confidence: 99%

Recent advances in the pharmacotherapy of osteoarthritis

Meera¹

2022

RRP

View full text Add to dashboard Cite

Introduction: Osteoarthritis (OA) is a common debilitating disease affecting the geriatric population. Management of osteoarthritis is a challenge for orthopedicians because till date there has been no such drug that can completely cure the disease or at least retard/arrest the disease progression. In addition to the currently available treatment options for OA like NSAIDs, opioids, nutraceuticals (glucosamine sulphate and chondroitin sulphate), many new drugs are being discovered or repurposed for use in osteoarthritis. Most of these recent drugs aim at retarding the disease progression rather than providing just a symptomatic relief. Materials and methods: All relevant articles regarding approved new drugs and pipeline drugs for osteoarthritis published between 2012–2021 were analysed. Those included animal studies as well as clinical trials. Some older articles were also referred to, provided they highlighted any significant data. The obtained data were analysed and compiled. Results and discussion: Broadly the recent drugs for OA can be classified based upon their site of action as (i) drugs targeting articular cartilage, (ii) drugs targeting inflammation, (iii) drugs targeting the subchondral bone, and (iv) drugs for relieving pain. Ranging from in vitro studies to clinical trials, these drugs are in various phases of drug discovery. Early diagnosis of OA and its management with a drug that retards disease progression rather than prescribing just a symptom reliever is very much necessary in the current situation. Conclusion: Need for new drugs for OA is increasing day by day. More number of clinical trials with larger sample sizes alone can satisfy the need of disease modifying drugs for OA. This review provides a deep insight into all the recent advances in the pharmacotherapy of osteoarthritis. Graphical abstract:

show abstract

Targeted treatment for osteoarthritis: drugs and delivery system

Cited by 61 publications

References 173 publications

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis

Carbon Nanotubes: An Optimistic Nanomaterial with Superfluity Characteristics in Drug Delivery for the Treatment of Arthritis

Recent advances in the pharmacotherapy of osteoarthritis

Contact Info

Product

Resources

About